ACHC Acadia Healthcare Company, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACHC Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Care Facilities
Current Price
Live
$16.79
Analyst Target
$19.07
+13.6%
Upside
52W High
$42.85
52W Low
$11.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$1.52B
P/E
14.47
ROE
3.7%
Profit margin
3.3%
Debt/Equity
0.74
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACHC's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns about operational efficiency and profitability sustainability. The company trades at a deeply discounted valuation with a Price/Book of 0.49 and a Graham Number of $30.01, suggesting potential undervaluation, but this is overshadowed by a severe earnings collapse—YoY earnings growth of -45.9% and a recent Q/Q decline of -46.8%. Despite strong historical earnings surprises and a buy recommendation from analysts, the lack of dividend, neutral insider activity, and prolonged price decline (down 58.7% over 1 year) signal deteriorating market sentiment. The absence of an Altman Z-Score further limits distress risk assessment, but the weak Piotroski score and negative growth trends suggest underlying financial stress.
Key Strengths
Strong historical earnings surprise track record (average +12.85% over last 4 quarters)
Attractive valuation metrics: P/E of 14.47, Price/Book of 0.49, and Price/Sales of 0.47
Graham Number of $30.01 suggests defensive fair value potential
Relatively low debt/equity ratio of 0.74 and healthy current ratio of 1.44
Buy recommendation from 14 analysts with a target price of $19.07
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and operational inefficiencies
Severe earnings contraction: -45.9% YoY and -46.8% Q/Q, signaling fundamental deterioration
Negative ROE (3.69%) and ROA (4.52%) despite positive operating margin (14.04%)
No dividend and zero payout ratio, indicating no shareholder return policy
Insider trading activity neutral with no buy activity in 6 months, suggesting lack of confidence
AI Fair Value Estimate
Based on comprehensive analysis
$28.5
+69.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
78
25
68
30
0
AI Verdict
cautious
Key drivers: Weak Piotroski F-Score and negative earnings growth, Attractive valuation metrics and historical earnings beats, Lack of dividend and neutral insider sentiment
Confidence
80%
Value
78/100
Ref P/E, PEG, Graham Number
Positives
- P/E of 14.47 is below sector average of 197.71
- Price/Book of 0.49 indicates deep discount to book value
- Graham Number of $30.01 suggests defensive fair value
Watchpoints
- Forward P/E of 9.64 is misleading due to negative earnings base
- Intrinsic value estimate of $8.12 is significantly below current price
Future
25/100
Ref Growth rates
Positives
- Analyst target price of $19.07 implies upside potential
- Recent 1-month price increase of +17.2% suggests short-term momentum
Watchpoints
- Earnings growth down -45.9% YoY and -46.8% Q/Q
- No visible growth in revenue (4.40% YoY) despite earnings collapse
- No PEG ratio available due to negative earnings
Past
68/100
Ref Historical trends
Positives
- Consistent earnings beats in 3 of last 4 quarters
- Average earnings surprise of +12.85% over last 4 quarters
- Historical track record of strong EPS performance
Watchpoints
- Significant drop in most recent Q/Q EPS growth (-13.3%)
- Year-over-year EPS growth of -20.9% indicates trend reversal
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.44 and quick ratio of 1.20 indicate short-term liquidity
- Debt/Equity of 0.74 is below sector average of 2.68
Watchpoints
- Piotroski F-Score of 4/9 is in the 'Weak' range, indicating poor financial health
- No Altman Z-Score available, but low F-Score raises distress risk concerns
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$16.79
Analyst Target
$19.07
Upside/Downside
+13.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACHC and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
Primary
|
-67.8% | -79.2% | -58.7% | -25.2% | +17.2% | +0.1% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
AHCO
AdaptHealth Corp.
Peer
|
-70.2% | -48.4% | +10.2% | +15.9% | +1.4% | +6.0% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
14.47
Forward P/E
9.64
PEG Ratio
N/A
P/B Ratio
0.49
P/S Ratio
0.47
EV/Revenue
1.24
EV/EBITDA
6.47
Market Cap
$1.52B
Profitability
Profit margins and return metrics
Profit Margin
3.29%
Operating Margin
14.04%
Gross Margin
41.78%
ROE
3.69%
ROA
4.52%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.4%
Earnings Growth
-45.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-46.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.74
Moderate
Current Ratio
1.44
Good
Quick Ratio
1.2
Good
Cash/Share
$1.29
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-05
$0.72
+9.2% surprise
2025-08-05
$0.83
+17.4% surprise
2025-05-12
$0.4
+12.0% surprise
Healthcare Sector Comparison
Comparing ACHC against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
P/E Ratio
14.47
This Stock
vs
197.75
Sector Avg
-92.7%
(Discount)
Return on Equity (ROE)
3.69%
This Stock
vs
-56.86%
Sector Avg
-106.5%
(Below Avg)
Profit Margin
3.29%
This Stock
vs
-20.8%
Sector Avg
-115.8%
(Weaker)
Debt to Equity
0.74
This Stock
vs
2.68
Sector Avg
-72.2%
(Less Debt)
Revenue Growth
4.4%
This Stock
vs
62.23%
Sector Avg
-92.9%
(Slower)
Current Ratio
1.44
This Stock
vs
3.45
Sector Avg
-58.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $1.52B | 14.47 | 3.7% | 3.3% | $16.79 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | 19.02 | 5.5% | 2.5% | $10.65 | |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-27 | YOUNG TODD S | Chief Financial Officer | Stock Award | 48,445 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Jefferies
2026-01-22
Buy
Hold
TD Cowen
2026-01-16
Buy
Buy
RBC Capital
2026-01-14
Outperform
Outperform
Mizuho
2025-12-18
Neutral
Neutral
Barclays
2025-12-04
Equal-Weight
Equal-Weight
RBC Capital
2025-12-03
Outperform
Outperform
Cantor Fitzgerald
2025-12-03
Neutral
Neutral
Keybanc
2025-12-03
Overweight
Overweight
UBS
2025-12-03
Buy
Buy
Deutsche Bank
2025-12-03
Buy
Buy
Past News Coverage
Recent headlines mentioning ACHC from our newsroom.
Newest → oldest
No matching news yet.